251 related articles for article (PubMed ID: 25210485)
1. Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.
Andrade AF; Borges KS; Silveira VS
Clin Med Insights Oncol; 2014; 8():95-100. PubMed ID: 25210485
[TBL] [Abstract][Full Text] [Related]
2. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
Burke MJ; Zalewska-Szewczyk B
Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
5. Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment.
Walenciak J; Wyka K; Janczar S; Młynarski W; Zalewska-Szewczyk B
Pharmacol Rep; 2019 Apr; 71(2):311-318. PubMed ID: 30826572
[TBL] [Abstract][Full Text] [Related]
6. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Pieters R; Hunger SP; Boos J; Rizzari C; Silverman L; Baruchel A; Goekbuget N; Schrappe M; Pui CH
Cancer; 2011 Jan; 117(2):238-49. PubMed ID: 20824725
[TBL] [Abstract][Full Text] [Related]
7. Delayed-type hypersensitivity in response to L-asparaginase in a case of acute lymphoblastic leukemia.
Narazaki H; Kaizu K; Miyatake C; Koizumi S; Asano T; Fujino O
J Nippon Med Sch; 2012; 79(6):489-93. PubMed ID: 23291850
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of PEG-asparaginase versus
Dai ZJ; Huang YQ; Lu Y
Transl Pediatr; 2021 Feb; 10(2):244-255. PubMed ID: 33708510
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.
Matteo C; Colombini A; Bettini LR; Porcu L; Barzaghi S; Ceruti T; Silvestri D; Amoroso A; Dell'Acqua F; Gotti G; Nastasi C; Zucchetti M; Rizzari C
Pediatr Blood Cancer; 2022 Sep; 69(9):e29753. PubMed ID: 35561075
[TBL] [Abstract][Full Text] [Related]
10. Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.
Vyas C; Jain S; Kapoor G; Mehta A; Takkar Chugh P
Pediatr Hematol Oncol; 2018; 35(5-6):331-340. PubMed ID: 30488741
[TBL] [Abstract][Full Text] [Related]
11. L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.
Mohamed SA; Elshal MF; Kumosani TA; Aldahlawi AM; Basbrain TA; Alshehri FA; Choudhry H
Int J Environ Res Public Health; 2016 Oct; 13(10):. PubMed ID: 27754445
[No Abstract] [Full Text] [Related]
12. Acute pancreatitis in children with acute lymphoblastic leukemia correlates with L-asparaginase dose intensity.
Chen CB; Chang HH; Chou SW; Yang YL; Lu MY; Jou ST; Chen HL; Ni YH; Lin DT; Chang MH; Wu JF
Pediatr Res; 2022 Aug; 92(2):459-465. PubMed ID: 34718353
[TBL] [Abstract][Full Text] [Related]
13. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Burke MJ
Future Oncol; 2014 Dec; 10(16):2615-27. PubMed ID: 24983955
[TBL] [Abstract][Full Text] [Related]
14. National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
Lussana F; Minetto P; Ferrara F; Chiaretti S; Specchia G; Bassan R
BMC Cancer; 2020 Oct; 20(1):956. PubMed ID: 33008391
[TBL] [Abstract][Full Text] [Related]
15. L-asparaginase activity and anti-L-asparaginase antibody as biomarkers in estimating PEG-asp-related anaphylaxis risk in childhood acute lymphoblastic leukemia patients.
Cui J; Jiang L; Xu B; Bai Y
Allergol Immunopathol (Madr); 2023; 51(3):28-35. PubMed ID: 37169557
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of treatment with L-asparaginase in children with acute lymphoblastic leukaemia, with a focus on silent inactivation and its influence on the treatment outcome.
Czogala M; Rogatko I; Pawińska-Wąsikowska K; Czogała W; Bal W; Ciebiera M; Chaber R; Chodała-Grzywacz A; Karolczyk G; Sztefko K; Balwierz W; Skoczeń S
Contemp Oncol (Pozn); 2022; 26(4):282-288. PubMed ID: 36816392
[TBL] [Abstract][Full Text] [Related]
17. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
Steiner M; Attarbaschi A; Kastner U; Dworzak M; Haas OA; Gadner H; Mann G
Pediatr Blood Cancer; 2007 Oct; 49(5):640-2. PubMed ID: 16941647
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
[TBL] [Abstract][Full Text] [Related]
19. [Mechanisms of development of side effects and drug resistance to asparaginase and ways to overcome them].
Alexandrova SS; Gladilina YA; Pokrovskaya MV; Sokolov NN; Zhdanov DD
Biomed Khim; 2022 Apr; 68(2):104-116. PubMed ID: 35485484
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
